Editas Medicine, Inc. (EDIT) vs YD Bio Limited Ordinary Shares (YDES)

A side-by-side comparison of Editas Medicine, Inc. and YD Bio Limited Ordinary Shares across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

EDIT

Editas Medicine, Inc.

$419M

$2.73HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

YDES

YD Bio Limited Ordinary Shares

$436M

$6.15HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — EDIT vs YDES

growth of $100 · dividends reinvested · last 1y

EDIT +9.0% (+9.0%/yr)YDES -40.9% (-40.9%/yr)EDIT compounded faster over this window

EDIT YDES

EDIT vs YDES: by the numbers

•YDES is the larger company ($436M vs $419M market cap).
•Both run net losses; EDIT's is the smaller (-157.32% vs -1392.61% net margin).

Metrics side by side

Valuation

Metric	EDIT	YDES
P/S ratio	8.91	N/A
P/B ratio	3.98	N/A

Profitability

Metric	EDIT	YDES
Gross margin	100.00%	-7.06%
Operating margin	-245.15%	-883.31%
Net margin	-157.32%	-1392.61%
ROE	-70.24%	-66.49%
ROIC	-48.61%	N/A

Growth (annualized)

Metric	EDIT	YDES
Revenue CAGR (5Y)	-10.34%	N/A
Total return CAGR (5Y)	-40.76%	N/A

Go deeper

Full EDIT analysis Full YDES analysis Interactive comparison tool

Dig into the metrics

Editas Medicine ROE YD Bio Limited Ordinary Shares ROE Editas Medicine operating margin YD Bio Limited Ordinary Shares operating margin Editas Medicine revenue growth YD Bio Limited Ordinary Shares revenue growth Editas Medicine free cash flow YD Bio Limited Ordinary Shares free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.